Gout Therapeutics

Gout Therapeutics


Global Gout Therapeutics Market to Reach US$10.8 Billion by 2030

The global market for Gout Therapeutics estimated at US$4.5 Billion in the year 2023, is expected to reach US$10.8 Billion by 2030, growing at a CAGR of 13.2% over the analysis period 2023-2030. NSAIDs, one of the segments analyzed in the report, is expected to record a 13.1% CAGR and reach US$4.7 Billion by the end of the analysis period. Growth in the Urate-Lowering Agents segment is estimated at 15.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 17.3% CAGR

The Gout Therapeutics market in the U.S. is estimated at US$1.2 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 17.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.1% and 11.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.

Global Gout Therapeutics Market - Key Trends and Drivers Summarized

How Is the Gout Therapeutics Market Evolving with the Rise in Chronic Diseases?

Gout is a chronic form of arthritis caused by elevated levels of uric acid in the blood, leading to the formation of painful crystals in joints. Gout therapeutics are essential in managing this condition, which is becoming increasingly common due to lifestyle factors such as poor diet, obesity, and the aging population. The rising prevalence of gout is prompting a growing demand for effective therapies that can manage both acute flare-ups and long-term uric acid levels. Traditional treatments like nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and colchicine are still widely used, but there is a significant shift towards novel urate-lowering therapies, such as xanthine oxidase inhibitors and biologics, aimed at providing better control of the condition and minimizing side effects.

What Are the Key Segments and Types of Gout Therapeutics?

Drug classes include NSAIDs, corticosteroids, colchicine, and urate-lowering therapies such as allopurinol, febuxostat, and pegloticase. Urate-lowering drugs are gaining more attention due to their efficacy in preventing recurrences and managing chronic gout. The market can also be divided into acute and chronic treatment types, where acute treatments are aimed at relieving pain and inflammation during a flare-up, while chronic treatments focus on lowering uric acid levels to prevent future attacks. Oral medications dominate the market, but injectable biologics are increasingly being used in severe cases of refractory gout. Geographically, North America and Europe lead the market due to high disease prevalence and advanced healthcare infrastructure, while the Asia-Pacific region is growing rapidly due to increasing awareness and healthcare access.

How Are Technological Advances Shaping the Future of Gout Treatment?

Technological advancements in gout therapeutics are transforming the way the disease is managed, particularly with the rise of biologics and personalized medicine. Biologics like pegloticase, which is used to treat severe, refractory gout, have proven effective where traditional treatments have failed. Additionally, research into genetic markers and personalized treatment plans is gaining traction, allowing for tailored therapies based on an individual’s specific uric acid metabolism. Continuous innovation in drug delivery systems, such as extended-release formulations and injectable biologics, is enhancing patient compliance and providing more sustained control of uric acid levels. Moreover, telemedicine and digital health platforms are facilitating better patient-doctor communication, enabling real-time monitoring and adjustments to treatment plans, particularly for long-term management.

What Factors Are Driving the Growth in the Gout Therapeutics Market?

The growth in the gout therapeutics market is driven by several factors, including the increasing prevalence of gout worldwide, especially in developed nations where lifestyle-related risk factors such as poor diet and obesity are on the rise. The growing aging population, who are more susceptible to chronic conditions, is also boosting the demand for effective gout management. Furthermore, advancements in drug development, particularly the rise of biologics and novel urate-lowering therapies, are expanding treatment options for patients with refractory gout. Increased awareness of gout as a serious chronic condition, rather than just an acute issue, is driving earlier diagnosis and treatment, while improved healthcare infrastructure in emerging markets is broadening access to advanced therapies.

Select Competitors (Total 42 Featured) -
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Grunenthal Group
  • Horizon Pharma Plc
  • Ironwood Pharmaceuticals, Inc.
  • JW Pharmaceutical
  • Merck& Co., Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals.
  • Savient Pharmaceuticals
  • Selecta Biosciences, Inc.
  • Takeda Pharmaceutical Company Ltd.
  • Teijin Pharma Ltd.


Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Gout Therapeutics – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Gout and Associated Comorbidities Spurs Growth in Gout Therapeutics
Increasing Focus on Novel Drug Development Strengthens Business Case for Gout Therapeutics
Technological Advancements in Precision Medicine Drive Adoption of Personalized Gout Treatment
Growing Demand for Biologics Expands Addressable Market for Gout Therapeutics
Rising Geriatric Population Drives Demand for Effective Gout Management Solutions
Increasing Awareness of Chronic Gout and Treatment Options Spurring Market Demand
Rising Healthcare Expenditure and Access to Advanced Therapies Strengthen Growth in Developed Markets
Emergence of Novel Urate-Lowering Therapies Spurs Demand for Advanced Treatment Options
Growing Focus on Reducing Flare-Ups and Long-Term Management of Gout Drives Market Growth
Increasing Use of Combination Therapies for Better Management of Refractory Gout Expands Market
Patient Preference for Less Invasive and Effective Treatment Modalities Generates Demand
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Gout Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Gout Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Gout Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Urate-Lowering Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Urate-Lowering Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Urate-Lowering Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Colchicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Colchicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Colchicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 14: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 15: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Chronic Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 17: World Historic Review for Chronic Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 18: World 16-Year Perspective for Chronic Gout by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Acute Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 20: World Historic Review for Acute Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 21: World 16-Year Perspective for Acute Gout by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 22: World Gout Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 23: USA Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: USA Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: USA 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 26: USA Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: USA Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: USA 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
CANADA
TABLE 29: Canada Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: Canada Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: Canada 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 32: Canada Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Canada 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
JAPAN
Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 35: Japan Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Japan Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Japan 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 38: Japan Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Japan Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Japan 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
CHINA
Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 41: China Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: China Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: China 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 44: China Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: China Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: China 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
EUROPE
Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 47: Europe Recent Past, Current & Future Analysis for Gout Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 48: Europe Historic Review for Gout Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Europe 16-Year Perspective for Gout Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 50: Europe Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Europe 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
FRANCE
Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 56: France Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: France Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: France 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 59: France Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: France Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: France 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
GERMANY
Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 62: Germany Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Germany Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Germany 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 65: Germany Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Germany Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Germany 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
ITALY
TABLE 68: Italy Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Italy Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Italy 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 71: Italy Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Italy 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
UNITED KINGDOM
Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 74: UK Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: UK Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: UK 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 77: UK Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: UK Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: UK 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
SPAIN
TABLE 80: Spain Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Spain Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Spain 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 83: Spain Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Spain Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Spain 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
RUSSIA
TABLE 86: Russia Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Russia Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Russia 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 89: Russia Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Russia Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Russia 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Rest of Europe Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Rest of Europe 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Rest of Europe Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Rest of Europe 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Gout Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 99: Asia-Pacific Historic Review for Gout Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Asia-Pacific 16-Year Perspective for Gout Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Asia-Pacific Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Asia-Pacific 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
AUSTRALIA
Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 107: Australia Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Australia Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Australia 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 110: Australia Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Australia Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Australia 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
INDIA
Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 113: India Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: India Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: India 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 116: India Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: India Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: India 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 119: South Korea Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: South Korea Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: South Korea 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 122: South Korea Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: South Korea Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: South Korea 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: Rest of Asia-Pacific Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: Rest of Asia-Pacific Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
LATIN AMERICA
Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 131: Latin America Recent Past, Current & Future Analysis for Gout Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 132: Latin America Historic Review for Gout Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Latin America 16-Year Perspective for Gout Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 134: Latin America Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Latin America Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Latin America 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 137: Latin America Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 140: Argentina Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Argentina Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Argentina 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 143: Argentina Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Argentina Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Argentina 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
BRAZIL
TABLE 146: Brazil Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Brazil Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Brazil 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 149: Brazil Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Brazil Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Brazil 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
MEXICO
TABLE 152: Mexico Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Mexico Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Mexico 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 155: Mexico Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Mexico Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Mexico 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Rest of Latin America Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Rest of Latin America 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Rest of Latin America Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Rest of Latin America 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
MIDDLE EAST
Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 164: Middle East Recent Past, Current & Future Analysis for Gout Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 165: Middle East Historic Review for Gout Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Middle East 16-Year Perspective for Gout Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 167: Middle East Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: Middle East Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Middle East 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 170: Middle East Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
IRAN
TABLE 173: Iran Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Iran Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Iran 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 176: Iran Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Iran Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Iran 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
ISRAEL
TABLE 179: Israel Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Israel Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Israel 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 182: Israel Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Israel Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Israel 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Saudi Arabia Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Saudi Arabia 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Saudi Arabia Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Saudi Arabia 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 191: UAE Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: UAE Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: UAE 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 194: UAE Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: UAE Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: UAE 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: Rest of Middle East Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: Rest of Middle East 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: Rest of Middle East Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: Rest of Middle East 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
AFRICA
Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 203: Africa Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: Africa Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Africa 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2024 & 2030
TABLE 206: Africa Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: Africa Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: Africa 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings